CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, announced today publication of MRI imaging ...
Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results